Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11831543,relative bioavailability,"The relative bioavailability, in terms of area under the curve values, of lovastatin (156%) and lovastatin acid (124%) was greater from lovastatin ER tablets as compared with lovastatin IR tablets when given with breakfast.",Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831543/),%,156,1439,DB00227,Lovastatin
,11831543,relative bioavailability,"The relative bioavailability, in terms of area under the curve values, of lovastatin (156%) and lovastatin acid (124%) was greater from lovastatin ER tablets as compared with lovastatin IR tablets when given with breakfast.",Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831543/),%,124,1440,DB00227,Lovastatin
,11831543,bioavailability,An even greater increase in the bioavailability of lovastatin (261%) and lovastatin acid (231%) was observed when the lovastatin ER tablets were administered under fasting conditions.,Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831543/),%,261,1441,DB00227,Lovastatin
,11831543,bioavailability,An even greater increase in the bioavailability of lovastatin (261%) and lovastatin acid (231%) was observed when the lovastatin ER tablets were administered under fasting conditions.,Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831543/),%,231,1442,DB00227,Lovastatin
,2328306,areas under the whole blood concentration-time profiles,"Similarly, mean areas under the whole blood concentration-time profiles were not significantly different with or without concomitant lovastatin (61823 +/- 27295 vs 41470 +/- 10312 ng h ml-1; p = 0.13).","Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328306/),[h·ng] / [ml],61823,5028,DB00227,Lovastatin
,2328306,areas under the whole blood concentration-time profiles,"Similarly, mean areas under the whole blood concentration-time profiles were not significantly different with or without concomitant lovastatin (61823 +/- 27295 vs 41470 +/- 10312 ng h ml-1; p = 0.13).","Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328306/),[h·ng] / [ml],41470,5029,DB00227,Lovastatin
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],9.6,9523,DB00227,Lovastatin
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],13.7,9524,DB00227,Lovastatin
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],34.3,9525,DB00227,Lovastatin
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],43.9,9526,DB00227,Lovastatin
,15811174,Serum concentration,"Serum concentration of cerivastatin at 6 h after taking the last dose (0.15 mg) was 8062.5 ng/L, which was almost 5.7 times higher than that of normal persons.",Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811174/),[ng] / [l],8062.5,9832,DB00227,Lovastatin
,15811174,half-life,"The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls.",Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811174/),h,22.4,9833,DB00227,Lovastatin
,15811174,half-life,"The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls.",Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811174/),h,2.4,9834,DB00227,Lovastatin
<,26802130,tumor to plasma partition coefficient,"SVA exposure in tECF was <33.8 ± 11.9 µg/l per hour, whereas the tumor to plasma partition coefficient of SVA was <0.084 ± 0.008.",Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26802130/),,0.084,11170,DB00227,Lovastatin
,32918160,oral bioavailability,"However, due to its poor intrinsic water solubility, the drug is poorly absorbed from the gastrointestinal tract and exhibits a low oral bioavailability of approximately 5%.","A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32918160/),%,5,12006,DB00227,Lovastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),min,30,27657,DB00227,Lovastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15,27658,DB00227,Lovastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,2,27659,DB00227,Lovastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15.6,27660,DB00227,Lovastatin
,21189658,50% inhibition concentration,Lovastatin inhibited CYP3A4 enzyme activity with a 50% inhibition concentration of 6.06 µM.,"Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),μM,6.06,27930,DB00227,Lovastatin
,21189658,absolute bioavailability,"Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%).","Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),%,11.1,27931,DB00227,Lovastatin
,21189658,absolute bioavailability,"Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%).","Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),%,7.6,27932,DB00227,Lovastatin
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],3.20,28337,DB00227,Lovastatin
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],6.78,28338,DB00227,Lovastatin
,2125605,AUC0-24,"The systemic bioavailabilities of total (active plus potentially active) inhibitors for the two drugs were different, with the mean AUC value for lovastatin being 50% higher than that of pravastatin (mean +/- SEM AUC0-24 values of 285 +/- 25 and 189 +/- 13 ng-equiv x hr/mL, respectively, P less than .0001).",Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125605/),[h·ng-equiv] / [ml],285,29816,DB00227,Lovastatin
,2125605,AUC0-24,"The systemic bioavailabilities of total (active plus potentially active) inhibitors for the two drugs were different, with the mean AUC value for lovastatin being 50% higher than that of pravastatin (mean +/- SEM AUC0-24 values of 285 +/- 25 and 189 +/- 13 ng-equiv x hr/mL, respectively, P less than .0001).",Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125605/),[h·ng-equiv] / [ml],189,29817,DB00227,Lovastatin
,11073847,area under the RLP-C curve,"Before treatment, FH patients had significantly higher fasting and postprandial concentrations of lipoprotein remnants (plasma RLP-C 42+/-19 mg/dL and area under the RLP-C curve 415+/-82 mg.",High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073847/),mg,415,34138,DB00227,Lovastatin
,11073847,RE,"Postprandial RE in the Sf<1000 fraction, not total RE in plasma, was also significantly higher in FH patients than in control subjects (24+/-10 versus 6.3+/-5.9 mg.",High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073847/),,24,34139,DB00227,Lovastatin
,11073847,RE,"Postprandial RE in the Sf<1000 fraction, not total RE in plasma, was also significantly higher in FH patients than in control subjects (24+/-10 versus 6.3+/-5.9 mg.",High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073847/),,6.3,34140,DB00227,Lovastatin
,16389644,flow-rate,The mobile phase contained acetonitrile and 10 mm NaH2PO4 in the proportions 60:40 (v/v) with a flow-rate of 1 mL/min.,An automated blood sampling system to measure lovastatin level in plasma and faeces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389644/),[ml] / [min],1,36305,DB00227,Lovastatin
,16389644,maximum plasma concentration,"Following pharmacokinetic analysis, we identified that the maximum plasma concentration was around 1.18 +/- 0.08 microg/mL at concentration peak time 120 min and almost 78% of loading dose was accumulated in the faeces within 48 h after lovastatin administration (500 mg/kg, p.o.).",An automated blood sampling system to measure lovastatin level in plasma and faeces. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389644/),[μg] / [ml],1.18,36306,DB00227,Lovastatin
more,26572385,residence,The in vivo residence of thiomer placebo was more than 7h in rabbit.,Formulation of mucoadhesive gastric retentive drug delivery using thiolated xyloglucan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572385/),h,7,42157,DB00227,Lovastatin
,34094835,DC50,"Herein, we identified a powerful HMGCR-targeted PROTAC (21c) comprising a VHL ligand conjugated to lovastatin acid that potently degrades HMGCR in Insig-silenced HepG2 cells (DC50 = 120 nmol/L) and forms a stable ternary complex, as predicated by a holistic modeling protocol.",Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34094835/),[nM] / [l],120,43972,DB00227,Lovastatin
,12015788,C(max),"Mean (+/-) values for the C(max) of lovastatin were 1.04+/-0.43, 2.03+/-0.65 and 4.03+/-3.02 ng/ml for the 10, 20 and 40 mg dosage, respectively.",Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015788/),[ng] / [ml],1.04,44364,DB00227,Lovastatin
,12015788,C(max),"Mean (+/-) values for the C(max) of lovastatin were 1.04+/-0.43, 2.03+/-0.65 and 4.03+/-3.02 ng/ml for the 10, 20 and 40 mg dosage, respectively.",Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015788/),[ng] / [ml],2.03,44365,DB00227,Lovastatin
,12015788,C(max),"Mean (+/-) values for the C(max) of lovastatin were 1.04+/-0.43, 2.03+/-0.65 and 4.03+/-3.02 ng/ml for the 10, 20 and 40 mg dosage, respectively.",Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015788/),[ng] / [ml],4.03,44366,DB00227,Lovastatin
,12015788,AUC(0-48 h),"The corresponding values for the AUC(0-48 h) of lovastatin were 14.6+/-7.8, 34.1 +/-13.7, and 53.9+/-35.6 ng h/ml.",Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015788/),[h·ng] / [ml],14.6,44367,DB00227,Lovastatin
,12015788,AUC(0-48 h),"The corresponding values for the AUC(0-48 h) of lovastatin were 14.6+/-7.8, 34.1 +/-13.7, and 53.9+/-35.6 ng h/ml.",Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015788/),[h·ng] / [ml],34.1,44368,DB00227,Lovastatin
,12015788,AUC(0-48 h),"The corresponding values for the AUC(0-48 h) of lovastatin were 14.6+/-7.8, 34.1 +/-13.7, and 53.9+/-35.6 ng h/ml.",Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015788/),[h·ng] / [ml],53.9,44369,DB00227,Lovastatin
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,18.37,45135,DB00227,Lovastatin
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,26.08,45136,DB00227,Lovastatin
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,8.68,45137,DB00227,Lovastatin
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,22.67,45138,DB00227,Lovastatin
>,9620098,trough:peak ratios,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),%,80,47827,DB00227,Lovastatin
,9620098,elimination half-life,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),h,17-25,47828,DB00227,Lovastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],3607,52016,DB00227,Lovastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],12886,52017,DB00227,Lovastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],6,52018,DB00227,Lovastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],26,52019,DB00227,Lovastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],130,52020,DB00227,Lovastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],110,52021,DB00227,Lovastatin
,19277959,total run time,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),min,2.8,63151,DB00227,Lovastatin
,19277959,flow rate,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),[ml] / [min],0.50,63152,DB00227,Lovastatin
,9333107,area under the curve [AUC(0-24)],"The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine.","Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],249,63881,DB00227,Lovastatin
,9333107,area under the curve [AUC(0-24)],"The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine.","Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],241,63882,DB00227,Lovastatin
,9333107,AUC(0-24),The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28.,"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],243,63883,DB00227,Lovastatin
,9333107,AUC(0-24),The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28.,"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],459,63884,DB00227,Lovastatin
,32749629,mean dissolution time,"The dissolution parameters revealed a shortening of mean dissolution time from 10.99 to 6.82 min, increasing of dissolution rate during the first 10 min from 1253.15 to 1667.31 μg/min, and enhancing of dissolution efficiency after 60 min from 71.92 to 86.93% for SMV-LSTs versus the commercial SMV tablets.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),min,10,65999,DB00227,Lovastatin
,32749629,dissolution rate,"The dissolution parameters revealed a shortening of mean dissolution time from 10.99 to 6.82 min, increasing of dissolution rate during the first 10 min from 1253.15 to 1667.31 μg/min, and enhancing of dissolution efficiency after 60 min from 71.92 to 86.93% for SMV-LSTs versus the commercial SMV tablets.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),[μg] / [min],1253.,66000,DB00227,Lovastatin
,32749629,dissolution rate,"The dissolution parameters revealed a shortening of mean dissolution time from 10.99 to 6.82 min, increasing of dissolution rate during the first 10 min from 1253.15 to 1667.31 μg/min, and enhancing of dissolution efficiency after 60 min from 71.92 to 86.93% for SMV-LSTs versus the commercial SMV tablets.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),[μg] / [min],166,66001,DB00227,Lovastatin
,32749629,relative bioavailability,"The obtained data reflected an improvement in the relative bioavailability of SMV with 148.232% which was confirmed by the significant reduction of the levels of circulating total cholesterol, triglycerides that reached the normal level after 12 h.",Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32749629/),%,148.232,66002,DB00227,Lovastatin
,29469964,Cmax,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[ng] / [ml],2.1,69219,DB00227,Lovastatin
,29469964,Cmax,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[ng] / [ml],1.0,69220,DB00227,Lovastatin
,29469964,Cmax,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[ng] / [ml],0.4,69221,DB00227,Lovastatin
,29469964,AUC,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[h·ng] / [ml],12.1,69222,DB00227,Lovastatin
,29469964,AUC,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[h·ng] / [ml],4.5,69223,DB00227,Lovastatin
,29469964,AUC,"At equivalent doses, SVA exposure was 6.3- and 2.5-fold greater in 521CC and TC genotypes relative to 521TT (Cmax , 2.1 ± 0.2 vs 1.0 ± 0.5 vs 0.4 ± 0.3 ng/mL; P < .0001; and AUC, 12.1 ± 0.3 vs 4.5 ± 2.5 vs 1.9 ± 1.8 ng·h/mL; P < .0001).",Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469964/),[h·ng] / [ml],1.9,69224,DB00227,Lovastatin
,29702479,Maximum plasma concentration (cmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),[μg] / [ml],21.86,71173,DB00227,Lovastatin
,29702479,Maximum plasma concentration (cmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),[μg] / [ml],8.25,71174,DB00227,Lovastatin
,29702479,time to reach it (tmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),h,1.4,71175,DB00227,Lovastatin
,29702479,time to reach it (tmax),"Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL-1 and 1.4 h for the drug complex, 8.25 μg mL-1 and 3.0 h for free drug, respectively.",Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),h,3.0,71176,DB00227,Lovastatin
up to,29702479,Bioavailability,Bioavailability of the simvastatin complex relative to free drug was up to 167.0 %.,Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29702479/),%,167.0,71177,DB00227,Lovastatin
,15315157,Relative bioavailability,Relative bioavailability was 111.5 +/- 16.9% (Tp) and 110.4% +/- 9.6% (Tj).,Pharmacokinetic study on lovastatin sustained-release tablet and sustained-release capsule in Beagal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315157/),%,111.5,71524,DB00227,Lovastatin
,15315157,Relative bioavailability,Relative bioavailability was 111.5 +/- 16.9% (Tp) and 110.4% +/- 9.6% (Tj).,Pharmacokinetic study on lovastatin sustained-release tablet and sustained-release capsule in Beagal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315157/),%,110.4,71525,DB00227,Lovastatin
,17192506,area under the plasma concentration-time curve,"The mean (+/-SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 +/- 2.25 ng x h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 +/- 6.37 ng x h/mL; P = .013, Bonferroni test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[h·ng] / [ml],4.94,76394,DB00227,Lovastatin
,17192506,area under the plasma concentration-time curve,"The mean (+/-SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 +/- 2.25 ng x h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 +/- 6.37 ng x h/mL; P = .013, Bonferroni test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[h·ng] / [ml],16.35,76395,DB00227,Lovastatin
,17192506,oral clearance,"The mean (+/-SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 +/- 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 +/- 0.61 L/h; P < .05, Dunn's test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[l] / [h],4.80,76396,DB00227,Lovastatin
,17192506,oral clearance,"The mean (+/-SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 +/- 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 +/- 0.61 L/h; P < .05, Dunn's test).",Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192506/),[l] / [h],1.35,76397,DB00227,Lovastatin
,27226460,flow rate,"The separation of all compounds was achieved in about 6.2 min using a C18 reverse-phase fused-core(®) column (Ascentis(®) Express C18) and a mobile phase, which was composed of 2.00 ± 0.05 mM ammonium acetate buffer titrated to pH 3.8 with glacial acetic acid-acetonitrile (25:75, v/v), in isocratic mode at a flow rate of 0.500 mL/min.",Development and Validation of an LC-MS-MS Method for Determination of Simvastatin and Simvastatin Acid in Human Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226460/),[ml] / [min],0.500,78309,DB00227,Lovastatin
,27719741,terminal half-life,GSK2647544 was readily absorbed and its plasma concentration declined bi-exponentially with a terminal half-life ranging from 8 to 16 hours.,"Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers . ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27719741/),h,8 to 16,86740,DB00227,Lovastatin
<,19636709,total release of,Release of simvastatin from the cubic nanoparticles was limited both in 0.1 M hydrochloride solution containing 0.2% sodium lauryl sulfate and fasted-state simulated intestinal fluid with a total release of <3.0% at 10 h.,Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19636709/),%,3.0,87319,DB00227,Lovastatin
,19636709,relative oral bioavailability,The relative oral bioavailability of simvastatin cubic nanoparticles calculated on the basis of area under the curve was 241% compared to simvastatin crystal powder.,Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19636709/),%,241,87320,DB00227,Lovastatin
,18205133,flow-rate,"Chromatographic separation was carried out on an Acquity UPLC BEH C(18) column with mobile phase consisting of acetonitrile-water (containing 5 mmol/L ammonium acetate; 85:15, v/v) at a flow-rate of 0.35 mL/min.",Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205133/),[ml] / [min],0.35,90125,DB00227,Lovastatin
shorter,18205133,analysis time,The analysis time was shorter than 1.7 min per sample.,Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18205133/),-1·min,1.7,90126,DB00227,Lovastatin
,18206330,flow rate,"The analysis was carried out on an ACQUITY UPLCTM BEH C18 column (50 mm x 2.1 mm, i.d., 1.7 microm) with flow rate of 0.35 ml/min.",Determination of lovastatin in human plasma by ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18206330/),[ml] / [min],0.35,91537,DB00227,Lovastatin
,16484515,apparent volume of distribution,The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L.,Exenatide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),l,28.3,93631,DB00227,Lovastatin
,16484515,terminal half-life,The terminal half-life of the drug is 2.4 hours.,Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),h,2.4,93632,DB00227,Lovastatin
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,65,93633,DB00227,Lovastatin
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,75,93634,DB00227,Lovastatin
,27321165,IC50,"Although no significant inhibition by LBQ657 (an active metabolite of sacubitril) and valsartan was observed, sacubitril inhibited OATP1B1 and OATP1B3 in vitro, with IC50 of 1·91 and 3·81 μm, respectively.",In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321165/),μm,1·91,94193,DB00227,Lovastatin
,27321165,IC50,"Although no significant inhibition by LBQ657 (an active metabolite of sacubitril) and valsartan was observed, sacubitril inhibited OATP1B1 and OATP1B3 in vitro, with IC50 of 1·91 and 3·81 μm, respectively.",In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321165/),μm,3·81,94194,DB00227,Lovastatin
,16671968,absorption rate,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),1/[h],1,95456,DB00227,Lovastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,14,95457,DB00227,Lovastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2,95458,DB00227,Lovastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2.5,95459,DB00227,Lovastatin
,16671968,input rate (K(in)),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),[g] / [d·l],0.14,95460,DB00227,Lovastatin
,16671968,inhibition fraction of K(in),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),,0.21,95461,DB00227,Lovastatin
,16671968,dose,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95462,DB00227,Lovastatin
,16671968,L,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95463,DB00227,Lovastatin
,15737556,MTD,"The MTD was determined to be 7.5 mg/kg/day x 21 days, every 28 days.",A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737556/),[mg] / [d·kg],7.5,95586,DB00227,Lovastatin
,15737556,survival,No objective responses were seen but the median survival of patients on study was 7.5 months (mean 9.2 +/- 1.5 months).,A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737556/),month,7.5,95587,DB00227,Lovastatin
,15737556,survival,No objective responses were seen but the median survival of patients on study was 7.5 months (mean 9.2 +/- 1.5 months).,A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737556/),month,9,95588,DB00227,Lovastatin
,22358108,50% inhibition concentration (IC(50)),Simvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC(50)) of 3.0 μM.,"Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358108/),μM,3.0,95725,DB00227,Lovastatin
,22358108,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) values of diltiazem in the presence of simvastatin (1.0 mg/kg) were significantly (p < 0.05) higher (44.8%) than that of the control group.","Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358108/),%,44.8,95726,DB00227,Lovastatin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,97,99614,DB00227,Lovastatin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,98,99615,DB00227,Lovastatin
,21120461,C(max) (maximum plasma concentration) ratios,"The least-square mean between treatment C(max) (maximum plasma concentration) ratios (×100) were 97, 98, and 109% for ezetimibe, simvastatin and niacin, respectively.",Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21120461/),%,109,99616,DB00227,Lovastatin
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB00227,Lovastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB00227,Lovastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB00227,Lovastatin
,17323791,time to maximum plasma concentration (tmax),"In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours.",Exenatide effects on statin pharmacokinetics and lipid response. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323791/),h,4,102126,DB00227,Lovastatin
,23692066,peak plasma SMV concentration,The peak plasma SMV concentration increased from 2.3 μg/mL with pure SMV to 3.8 μg/mL with dendrimer formulations.,Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692066/),[μg] / [ml],2.3,104591,DB00227,Lovastatin
,23692066,peak plasma SMV concentration,The peak plasma SMV concentration increased from 2.3 μg/mL with pure SMV to 3.8 μg/mL with dendrimer formulations.,Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692066/),[μg] / [ml],3.8,104592,DB00227,Lovastatin
,16542205,half-life,"The half-life of the latter was significantly shorter in the nine carriers with a SLCO1B1*1b allele compared with the seven subjects with the wild-type SLCO1B1*1a/*1a genotype (12.2 +/- 1.6 h vs. 14.5 +/- 1.4 h, P = 0.01).","Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542205/),h,12.2,107239,DB00227,Lovastatin
,16542205,half-life,"The half-life of the latter was significantly shorter in the nine carriers with a SLCO1B1*1b allele compared with the seven subjects with the wild-type SLCO1B1*1a/*1a genotype (12.2 +/- 1.6 h vs. 14.5 +/- 1.4 h, P = 0.01).","Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542205/),h,14.5,107240,DB00227,Lovastatin
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],25,108570,DB00227,Lovastatin
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],14,108571,DB00227,Lovastatin
,16398595,Cmax,"The Cmax and area under the curve (AUC) of lovastatin were 22.42 ng/mL, and 80.47 higher than CRYR (p = 0.001 and 0.002, respectively).",Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398595/),[ng] / [ml],22.42,113280,DB00227,Lovastatin
,16398595,Cmax,The Cmax for lovastatin hydroxy-acid was 36.63 ng/mL higher than the Cmax of CRYR hydroxy-acid (p = 0.001).,Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398595/),[ng] / [ml],36.63,113281,DB00227,Lovastatin
,26519618,total run time,Polarity switch (positive-negative-positive ionization mode) was performed in a total run time of 4.0min.,"Validated UPLC-MS/MS method for simultaneous determination of simvastatin, simvastatin hydroxy acid and berberine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of simvastatin combined with berberine after oral administration in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519618/),min,4.0,113414,DB00227,Lovastatin
,33623369,PS,The mean PS was 12.3±2.1 µm.,"Preparation, Characterization and in vitro/in vivo Evaluation of Lovastatin-Loaded PLGA Microspheres by Local Administration for Femoral Head Necrosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33623369/),µm,12.3,113657,DB00227,Lovastatin
,33623369,drug-loading rate,The drug-loading rate (27.6% ± 2.9%) was calculated for three batches of MS.,"Preparation, Characterization and in vitro/in vivo Evaluation of Lovastatin-Loaded PLGA Microspheres by Local Administration for Femoral Head Necrosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33623369/),%,27.6,113658,DB00227,Lovastatin
,14691614,half-life,"The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% ( P<0.01), and half-life of simvastatin acid was shortened from 5.9+/-0.3 h to 3.7+/-0.5 h ( P<0.01) by carbamazepine.",Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14691614/),h,5.9,113992,DB00227,Lovastatin
,14691614,half-life,"The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% ( P<0.01), and half-life of simvastatin acid was shortened from 5.9+/-0.3 h to 3.7+/-0.5 h ( P<0.01) by carbamazepine.",Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14691614/),h,3.7,113993,DB00227,Lovastatin
,27048644,run time,"A volume of plasma sample of only 400 µL was processed by the solid phase extraction technique; then 20 µL of processed sample was run on a Phenomenex, Kinetix XB C18, 150 × 4.6 mm, 5 µm column using an isocratic mobile phase consisting of 10 mM ammonium formate buffer (pH 4.0 ± 0.3): acetonitrile (27 : 73, v/v) with a run time of 6.3 min.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),min,6.3,114026,DB00227,Lovastatin
,27048644,Cmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,10.61,114027,DB00227,Lovastatin
,27048644,Cmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,69.74,114028,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,77.58,114029,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,69.74,114030,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,190.71,114031,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,1.74,114032,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,25.36,114033,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,139.24,114034,DB00227,Lovastatin
,27048644,AUC0-inf,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,3.95,114035,DB00227,Lovastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,1.74,114036,DB00227,Lovastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,25.36,114037,DB00227,Lovastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,139.24,114038,DB00227,Lovastatin
,27048644,Tmax,"The Cmax, AUC0-inf and Tmax values obtained in our study were 10.61 ± 5.287, 77.58 ± 29.367 and 1.62 ± 0.436 for EZM; 69.74 ± 45.274, 190.71 ± 107.271 and 1.74 ± 0.480 for SS; and 25.36 ± 23.576, 139.24 ± 131.653 and 3.95 ± 0.671 for SSA, respectively.","Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27048644/),,3.95,114039,DB00227,Lovastatin
,11868800,maximum concentration (Cmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],8.49,124585,DB00227,Lovastatin
,11868800,maximum concentration (Cmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],16.3,124586,DB00227,Lovastatin
,11868800,time to Cmax (tmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,1.8,124587,DB00227,Lovastatin
,11868800,time to Cmax (tmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,1.7,124588,DB00227,Lovastatin
,11868800,terminal plasma half-life (t1/2),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,4.3,124589,DB00227,Lovastatin
,11868800,terminal plasma half-life (t1/2),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,3.7,124590,DB00227,Lovastatin
,11868800,area under the plasma concentration-time curve from zero to infinity (AUC0-infinity),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],53,124591,DB00227,Lovastatin
,11868800,area under the plasma concentration-time curve from zero to infinity (AUC0-infinity),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],85,124592,DB00227,Lovastatin
,11868800,Cmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],24.6,124593,DB00227,Lovastatin
,11868800,Cmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],17.8,124594,DB00227,Lovastatin
,11868800,tmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,3.7,124595,DB00227,Lovastatin
,11868800,tmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,4.1,124596,DB00227,Lovastatin
,11868800,t1/2,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,3.2,124597,DB00227,Lovastatin
,11868800,t1/2,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,4.3,124598,DB00227,Lovastatin
,11868800,AUC0-infinity,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],149,124599,DB00227,Lovastatin
,11868800,AUC0-infinity,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],105,124600,DB00227,Lovastatin
over,30167890,EE%,"With the weight ratio of TPGS-to-PLGA in organic phase of 30% and TPGS-to-lipid in aqueous phase of 35%, ST-TLPN exhibited core-shell structure, sub-100 nm size, EE% of over 90% and a slow release profile.",Fabrication of TPGS-Stabilized Liposome-PLGA Hybrid Nanoparticle Via a New Modified Nanoprecipitation Approach: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30167890/),%,90,124919,DB00227,Lovastatin
,21128704,relative bioavailability,"The relative bioavailability of simvastatin from optimized SLNs was found to be 220%, substantiating the protective action of SLNs against liver metabolism.",Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21128704/),%,220,129701,DB00227,Lovastatin
,20060469,bioavailability,"The oral lovastatin bioavailability was enhanced from 4% to 24% and 13% when the drug was administered from NLCs containing Myverol and SPC, respectively.",Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20060469/),%,4,129767,DB00227,Lovastatin
,20060469,bioavailability,"The oral lovastatin bioavailability was enhanced from 4% to 24% and 13% when the drug was administered from NLCs containing Myverol and SPC, respectively.",Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20060469/),%,24,129768,DB00227,Lovastatin
,20060469,bioavailability,"The oral lovastatin bioavailability was enhanced from 4% to 24% and 13% when the drug was administered from NLCs containing Myverol and SPC, respectively.",Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20060469/),%,13,129769,DB00227,Lovastatin
,15116058,inhibition constant,The in vitro results indicate that the maximum gemfibrozil inhibition of rosuvastatin OATP2-mediated uptake was 50%; the inhibition constant for the inhibitory process was 4.0 +/- 1.3 micromol/L.,The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116058/),[μM] / [l],4.0,131878,DB00227,Lovastatin
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,7.3,136145,DB00227,Lovastatin
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,9.3,136146,DB00227,Lovastatin
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,5.2,136147,DB00227,Lovastatin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136808,DB00227,Lovastatin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136809,DB00227,Lovastatin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136810,DB00227,Lovastatin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136811,DB00227,Lovastatin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136812,DB00227,Lovastatin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136813,DB00227,Lovastatin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],312,136814,DB00227,Lovastatin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136815,DB00227,Lovastatin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],3536,136816,DB00227,Lovastatin
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,9.4,136817,DB00227,Lovastatin
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,12.4,136818,DB00227,Lovastatin
,23469684,Tmax,"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,1.44,137307,DB00227,Lovastatin
,23469684,Cmax,"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),[μg] / [l],9.83,137308,DB00227,Lovastatin
,23469684,t1/2,"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,4.85,137309,DB00227,Lovastatin
,23469684,AUC(0-infinity),"Major pharmacokinetic parameters were as follows: Tmax 1.44 +/- 0.39 h, Cmax 9.83 +/- 2.41 microg x L(-1), t1/2 4.85 +/- 1.23 h and AUC(0-infinity) 40.32 +/- 6.82 microg x h x L(-1).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),[h·μg] / [l],40.32,137310,DB00227,Lovastatin
,23469684,t1/2,"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,5.65,137311,DB00227,Lovastatin
,23469684,Cmax,"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,5.65,137312,DB00227,Lovastatin
,23469684,AUC(0-infinity),"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,5.65,137313,DB00227,Lovastatin
,23469684,AUC(0-infinity),"Significant differences in t1/2, but not Cmax and AUC(0-infinity), were observed between G/A, G/T or G/G carriers and non-G carriers (5.65 +/- 0.50 h vs 4.41 +/- 1.31 h, P < 0.05).","Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469684/),h,4.41,137314,DB00227,Lovastatin
,29716858,maximum plasma concentration Cmax,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[ng] / [ml],2.47,140860,DB00227,Lovastatin
,29716858,maximum plasma concentration Cmax,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[ng] / [ml],5.66,140861,DB00227,Lovastatin
,29716858,area under time versus concentration curve from 0 to 10 hours AUC0-10,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[h·ng] / [ml],15.10,140862,DB00227,Lovastatin
,29716858,area under time versus concentration curve from 0 to 10 hours AUC0-10,Clarithromycin co-treatment resulted in 2.3 fold increase in maximum plasma concentration Cmax (from 2.47±0.34 ng.mL-1 to 5.66±1.18 ng.mL-1; p<0.05) and 3.9 fold increase in area under time versus concentration curve from 0 to 10 hours AUC0-10 (from 15.10±3.73 ng.hr.mL-1 to 58.49±15.73 ng.hr.mL-1; p<0.05) of simvastatin.,Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716858/),[h·ng] / [ml],58.49,140863,DB00227,Lovastatin
,19764585,recovery rates,"The established method was able to determine lovastatin in human plasma over the range of 0.03125-64 microg/L, with recovery rates ranging from 96% to 102%.",[Determination of lovastatin and its active metabolites in human plasma with high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764585/),%,96,142223,DB00227,Lovastatin
,19764585,recovery rates,"The established method was able to determine lovastatin in human plasma over the range of 0.03125-64 microg/L, with recovery rates ranging from 96% to 102%.",[Determination of lovastatin and its active metabolites in human plasma with high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764585/),%,102,142224,DB00227,Lovastatin
,22718749,limit of detection,"Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[pg] / [ml],0.68,146836,DB00227,Lovastatin
,22718749,limit of quantification,"Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[pg] / [ml],2.30,146837,DB00227,Lovastatin
,22718749,maximum plasma concentration,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[ng] / [ml],17.5,146838,DB00227,Lovastatin
,22718749,time to reach that concentration,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),h,3.5,146839,DB00227,Lovastatin
,22718749,elimination half life,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),h,18.09,146840,DB00227,Lovastatin
,20824619,absolute oral bioavailability (F),"However, after oral administration of nicardipine with 1 mg/kg of oral lovastatin, the AUC of nicardipine was significantly greater (by 67.4%), and the extent of absolute oral bioavailability (F) of nicardipine was increased (by 38.5%).",Effects of lovastatin on the pharmacokinetics of nicardipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20824619/),%,38.5,147218,DB00227,Lovastatin
,12603176,areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)),The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L.,"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],4586,148575,DB00227,Lovastatin
,12603176,areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)),The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L.,"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],4928,148576,DB00227,Lovastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],30.5,148577,DB00227,Lovastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],20.0,148578,DB00227,Lovastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],43.0,148579,DB00227,Lovastatin
,12603176,AUC(tau),"AUC(tau) values for simvastatin were 30.5 (23.1-40.2) and 20.0 (15.9-25.1) micro g * h/L and for beta-hydroxyacid simvastatin 43.0 (32.1-57.8) and 23.4 (16.7-32.6) micro g * h/L in treatments B and C, respectively.","Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603176/),[h·μg] / [l],23.4,148580,DB00227,Lovastatin
,25138349,solubilizing capacity,Tween-80 also showed good solubilizing capacity which was 117 mg/ml.,"Preparation and evaluation of SEDDS of simvastatin by in vivo, in vitro and ex vivo technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138349/),[mg] / [ml],117,152763,DB00227,Lovastatin
,22229827,T(max),"Additionally, the T(max) of simvastatin nanocrystal group was 1.99 h, comparing to 2.88 h of reference group.",Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22229827/),h,1.99,159889,DB00227,Lovastatin
,22229827,T(max),"Additionally, the T(max) of simvastatin nanocrystal group was 1.99 h, comparing to 2.88 h of reference group.",Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22229827/),h,2.88,159890,DB00227,Lovastatin
,25709403,encapsulation efficiency,"Mean size of the microspheres was 2.65±0.69 μm; the encapsulation efficiency was 92.5%±3.6%, and drug loading was 16.7%±2.1%.",Development of lovastatin-loaded poly(lactic acid) microspheres for sustained oral delivery: in vitro and ex vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25709403/),%,92.5,161212,DB00227,Lovastatin
,25709403,drug loading,"Mean size of the microspheres was 2.65±0.69 μm; the encapsulation efficiency was 92.5%±3.6%, and drug loading was 16.7%±2.1%.",Development of lovastatin-loaded poly(lactic acid) microspheres for sustained oral delivery: in vitro and ex vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25709403/),%,16.7,161213,DB00227,Lovastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],7.8,167666,DB00227,Lovastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],15.4,167667,DB00227,Lovastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],21.7,167668,DB00227,Lovastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],43.3,167669,DB00227,Lovastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],74.2,167670,DB00227,Lovastatin
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],58.6,167671,DB00227,Lovastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],365,167672,DB00227,Lovastatin
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],287,167673,DB00227,Lovastatin
,23971207,Cmax,"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),[ng] / [ml],0.49,168487,DB00227,Lovastatin
,23971207,t(max),"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),h,1.6,168488,DB00227,Lovastatin
,23971207,AUC(0-infinity),"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),[h·ng] / [ml],1.08,168489,DB00227,Lovastatin
,23971207,t1/2kel,"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),h,2.14,168490,DB00227,Lovastatin
,23971207,MRT,"Mean (+/- SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 +/- 0.21 ng/ml, t(max) = 1.6 +/- 1.1 h, AUC(0-infinity) = 1.08 +/- 0.57 h x ng/ml, t1/2kel = 2.14 +/-1.3 h and MRT = 3.08 +/- 1.52 h.",Pharmacokinetics of orally administered simvastatin in turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23971207/),h,3.08,168491,DB00227,Lovastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],48.0,169350,DB00227,Lovastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],14.1,169351,DB00227,Lovastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],3.10,169352,DB00227,Lovastatin
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,39.31,176348,DB00227,Lovastatin
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,50,176349,DB00227,Lovastatin
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,15.77,176350,DB00227,Lovastatin
,11259986,Cmax,"The mean Cmax and AUC(0,24 h) of simvastatin (95% confidence interval) when given alone were 8.76 (6.72-11.41) ng ml(-1) and 60.36 (47.15-77.28) ng ml(-1) h.",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),[ng] / [ml],8.76,177867,DB00227,Lovastatin
,11259986,"AUC(0,24 h)","The mean Cmax and AUC(0,24 h) of simvastatin (95% confidence interval) when given alone were 8.76 (6.72-11.41) ng ml(-1) and 60.36 (47.15-77.28) ng ml(-1) h.",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),[h·ng] / [ml],60.36,177868,DB00227,Lovastatin
,11259986,time to peak concentration (tmax,"No significant differences were observed in either time to peak concentration (tmax was 1.0 h for simvastatin alone and 1.5 h for the combination) or in the half-life (t1/2,z was 8.5 h in both cases).",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),h,1.0,177869,DB00227,Lovastatin
,11259986,time to peak concentration (tmax,"No significant differences were observed in either time to peak concentration (tmax was 1.0 h for simvastatin alone and 1.5 h for the combination) or in the half-life (t1/2,z was 8.5 h in both cases).",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),h,1.5,177870,DB00227,Lovastatin
,11259986,"half-life (t1/2,z","No significant differences were observed in either time to peak concentration (tmax was 1.0 h for simvastatin alone and 1.5 h for the combination) or in the half-life (t1/2,z was 8.5 h in both cases).",The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259986/),h,8.5,177871,DB00227,Lovastatin
,25323804,t max,"Moreover, the median t max of simvastatin acid occurred earlier (1.8 h) when combined compared to 3.0 h when administered alone.","Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323804/),h,1.8,180659,DB00227,Lovastatin
,25323804,t max,"Moreover, the median t max of simvastatin acid occurred earlier (1.8 h) when combined compared to 3.0 h when administered alone.","Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25323804/),h,3.0,180660,DB00227,Lovastatin
,10934672,AUC0-infinity,The mean AUC0-infinity of total simvastatin acid was 74.55 ng x h/mL when simvastatin was given alone and 67.55 ng x h/mL when simvastatin and irbesartan were given concomitantly.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),[h·ng] / [ml],74.55,181395,DB00227,Lovastatin
,10934672,AUC0-infinity,The mean AUC0-infinity of total simvastatin acid was 74.55 ng x h/mL when simvastatin was given alone and 67.55 ng x h/mL when simvastatin and irbesartan were given concomitantly.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),[h·ng] / [ml],67.55,181396,DB00227,Lovastatin
,10934672,time to peak serum concentration,The time to peak serum concentration for both treatments was 3 hours.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),h,3,181397,DB00227,Lovastatin
,23631382,PS,The optimised NE showed PS of 132 ± 9 nm and zeta potential of 17.1 ± 1.2 mV.,"Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631382/),nm,132,183028,DB00227,Lovastatin
,23631382,zeta potential,The optimised NE showed PS of 132 ± 9 nm and zeta potential of 17.1 ± 1.2 mV.,"Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631382/),mv,17.1,183029,DB00227,Lovastatin
,23631382,relative bioavailability,Pharmacokinetic studies showed relative bioavailability of simvastatin NE was 369.0% with respect to PD suspension.,"Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23631382/),%,369.0,183030,DB00227,Lovastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,16.0,183649,DB00227,Lovastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,43.5,183650,DB00227,Lovastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,15.2,183651,DB00227,Lovastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,28.4,183652,DB00227,Lovastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,5.2,183653,DB00227,Lovastatin
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,6.3,183654,DB00227,Lovastatin
,25387217,elimination half-life,The elimination half-life of albiglutide is approximately 5 days.,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25387217/),d,5,188501,DB00227,Lovastatin
,25387217,Clearance,Clearance of albiglutide is 67 mL/h with between-subject variability of 34.9%; no covariates have been identified that would require dose adjustment of albiglutide.,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25387217/),[ml] / [h],67,188502,DB00227,Lovastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00227,Lovastatin
,26425076,polydispersity index,The particles had almost spherical and uniform shapes and were well dispersed with a particle size of <50 nm (23.5 ± 1.6 nm) and a low polydispersity index (0.17 ± 0.05 mV).,Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26425076/),mv,0.17,188720,DB00227,Lovastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],151,190014,DB00227,Lovastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],75,190015,DB00227,Lovastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],17,190016,DB00227,Lovastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],548,190017,DB00227,Lovastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],167,190018,DB00227,Lovastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],289,190019,DB00227,Lovastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],24 319,190020,DB00227,Lovastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],26 760,190021,DB00227,Lovastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],15 565,190022,DB00227,Lovastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],14 571,190023,DB00227,Lovastatin
,18196524,total chromatographic run time,The total chromatographic run time was 3.0 min.,Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS/MS without polarity switch: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196524/),min,3.0,190848,DB00227,Lovastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],22.2,192219,DB00227,Lovastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],21.3,192220,DB00227,Lovastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],61.3,192221,DB00227,Lovastatin
,7875191,AUC,"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1.",Lack of interaction between ramipril and simvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),[h·ng] / [ml],57.6,192222,DB00227,Lovastatin
,7875191,urinary excretion,The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose.,Lack of interaction between ramipril and simvastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,25.2,192223,DB00227,Lovastatin
,7875191,urinary excretion,The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose.,Lack of interaction between ramipril and simvastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,24.1,192224,DB00227,Lovastatin
,7875191,maximum percentage inhibition,"The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%.",Lack of interaction between ramipril and simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,94.6,192225,DB00227,Lovastatin
,7875191,maximum percentage inhibition,"The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%.",Lack of interaction between ramipril and simvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875191/),%,94.1,192226,DB00227,Lovastatin
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],190,193159,DB00227,Lovastatin
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],197,193160,DB00227,Lovastatin
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],368,193161,DB00227,Lovastatin
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],324,193162,DB00227,Lovastatin
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.8,193163,DB00227,Lovastatin
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.4,193164,DB00227,Lovastatin
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,3.7,193165,DB00227,Lovastatin
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,4.7,193166,DB00227,Lovastatin
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB00227,Lovastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB00227,Lovastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB00227,Lovastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB00227,Lovastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB00227,Lovastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB00227,Lovastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB00227,Lovastatin
lower,31505985,bioavailability,Lovastatin shows low bioavailability (lower than 5%) after oral administration because of the poor aqueous solubility and widely metabolized by CYP3A4.,The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31505985/),%,5,197251,DB00227,Lovastatin
up to,31505985,absolute bioavailability,"The oral bioavailability of lovastatin and lovastatin acid after oral administration of lovastatin solid dispersion with 10 mg/kg kaempferol (CYP3A4 inhibitor) were increased about 3.79-fold and 2.51-fold than that of lovastatin suspension, and the absolute bioavailability of lovastatin was up to 33.0%.",The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31505985/),%,33.0,197252,DB00227,Lovastatin
,23109219,maximum plasma drug concentration (C(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],81.56,200393,DB00227,Lovastatin
,23109219,maximum plasma drug concentration (C(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],9.40,200394,DB00227,Lovastatin
,23109219,time to reach C(max) (t(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,0.93,200395,DB00227,Lovastatin
,23109219,time to reach C(max) (t(max)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,1.25,200396,DB00227,Lovastatin
,23109219,elimination half-life (t(½)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,24.32,200397,DB00227,Lovastatin
,23109219,elimination half-life (t(½)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,18.90,200398,DB00227,Lovastatin
,23109219,area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],579.06,200399,DB00227,Lovastatin
,23109219,area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)),"The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C(max)) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C(max) (t(max)) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t(½)) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(last)) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],126.01,200400,DB00227,Lovastatin
,23109219,C(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],11.92,200401,DB00227,Lovastatin
,23109219,C(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[ng] / [ml],3.37,200402,DB00227,Lovastatin
,23109219,t(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,0.98,200403,DB00227,Lovastatin
,23109219,t(max),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,3.73,200404,DB00227,Lovastatin
,23109219,t(½),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,4.19,200405,DB00227,Lovastatin
,23109219,t(½),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),h,7.65,200406,DB00227,Lovastatin
,23109219,AUC(last),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],33.63,200407,DB00227,Lovastatin
,23109219,AUC(last),"The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C(max) 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t(max) 0.98 ± 0.28 and 3.73 ± 1.68 h, t(½) 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC(last) 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL.","Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23109219/),[h·ng] / [ml],32.50,200408,DB00227,Lovastatin
,19721239,total run time of analysis,The total run time of analysis was 6 min with the retention time of lovastatin being 4.3 min.,A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),min,6,201844,DB00227,Lovastatin
,19721239,retention time,The total run time of analysis was 6 min with the retention time of lovastatin being 4.3 min.,A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),min,4.3,201845,DB00227,Lovastatin
,19721239,limit of detection (LOD),"The limit of detection (LOD) and limit of quantification (LOQ) for lovastatin were 0.5 and 1 ng/ml, respectively.",A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),[ng] / [ml],0.5,201846,DB00227,Lovastatin
,19721239,limit of quantification (LOQ),"The limit of detection (LOD) and limit of quantification (LOQ) for lovastatin were 0.5 and 1 ng/ml, respectively.",A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),[ng] / [ml],1,201847,DB00227,Lovastatin
,19721239,relative recovery,The mean relative recovery of lovastatin from human plasma by the developed method was 88.61+/-7.00%.,A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721239/),%,88.61,201848,DB00227,Lovastatin
,19188036,flow rate,"The chromatographic separation was achieved using an isocratic mobile phase consisting of a mixture of acetonitrile and 0.5% formic acid (90:10 (v/v), pH 3.5) flowing through C18 column at a flow rate of 0.2ml/min.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),[ml] / [min],0.2,203269,DB00227,Lovastatin
,19188036,m,"Ions were monitored in positive mode and the mass transitions measured were m/z 268.1-->m/z 103.2, m/z 441.3-->m/z 325.1 and m/z 260.0-->m/z 129.5 for MET, SIM and WIS, respectively.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),,268.1,203270,DB00227,Lovastatin
,8889048,binding ability,"The binding ability of SVH to CT was 66.71% (pH 2), 87.44% (pH 5) and 92.11% (pH 7), respectively.",Drug interaction between simvastatin and cholestyramine in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889048/),%,66.71,204073,DB00227,Lovastatin
,8889048,binding ability,"The binding ability of SVH to CT was 66.71% (pH 2), 87.44% (pH 5) and 92.11% (pH 7), respectively.",Drug interaction between simvastatin and cholestyramine in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889048/),%,87.44,204074,DB00227,Lovastatin
,8889048,binding ability,"The binding ability of SVH to CT was 66.71% (pH 2), 87.44% (pH 5) and 92.11% (pH 7), respectively.",Drug interaction between simvastatin and cholestyramine in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889048/),%,92.11,204075,DB00227,Lovastatin
,10702889,AUCt ratios,"The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, respectively.",Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702889/),,1.6,206127,DB00227,Lovastatin
,10702889,AUCt ratios,"The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, respectively.",Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702889/),,2.0,206128,DB00227,Lovastatin
,22544712,flow rate,"The reconstituted samples were chromatographed on an Alltima HP C(18) column using an isocratic solvent mixture [acetonitrile-5 mm ammonium acetate (pH 4.5), 85:15 (v/v)] at a flow rate of 1.0 mL/min.",Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),[ml] / [min],1.0,207551,DB00227,Lovastatin
,22544712,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),min,3.0,207552,DB00227,Lovastatin
,24154936,Tmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.8,208386,DB00227,Lovastatin
,24154936,Tmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.9,208387,DB00227,Lovastatin
,24154936,Cmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],2 091,208388,DB00227,Lovastatin
,24154936,Cmax,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],2 323,208389,DB00227,Lovastatin
,24154936,AUC0-t,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 123.88,208390,DB00227,Lovastatin
,24154936,AUC0-t,The main pharmacokinetic parameters for the single and multiple doses were as -follows: Niacin: Tmax were 3.8±1.5 h and 3.9±2.0 h; Cmax were 2 091±1 315 ng/ml and 2 323±1 542 ng/ml; AUC0-t were 4 123.88±3 138.48 ng ∙ h/ml and 4 385.98±3 127.05 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 385.98,208391,DB00227,Lovastatin
,24154936,Tmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,4.7,208392,DB00227,Lovastatin
,24154936,Tmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,3.8,208393,DB00227,Lovastatin
,24154936,Cmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],1 057,208394,DB00227,Lovastatin
,24154936,Cmax,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],1 087,208395,DB00227,Lovastatin
,24154936,AUC0-t,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 012.49,208396,DB00227,Lovastatin
,24154936,AUC0-t,NUA: Tmax were 4.7±1.7 h and 3.8±1.5 h; Cmax were 1 057±549 ng/ml and 1 087±470 ng/ml; AUC0-t were 4 012.49±2 168.68 ng ∙ h/ml and 4 040.45±1 886.57 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],4 040.45,208397,DB00227,Lovastatin
,24154936,Tmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,1.8,208398,DB00227,Lovastatin
,24154936,Tmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,2.5,208399,DB00227,Lovastatin
,24154936,Cmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],3.15,208400,DB00227,Lovastatin
,24154936,Cmax,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],4.87,208401,DB00227,Lovastatin
,24154936,AUC0-t,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],9.03,208402,DB00227,Lovastatin
,24154936,AUC0-t,Simvastatin: Tmax were 1.8±1.0 h and 2.5±2.5 h; Cmax were 3.15±1.67 ng/ml and 4.87±4.11 ng/ml; AUC0-t were 9.03±5.10 ng ∙ h/ml and 17.63±13.93 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],17.63,208403,DB00227,Lovastatin
,24154936,Tmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,5.8,208404,DB00227,Lovastatin
,24154936,Tmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),h,6.5,208405,DB00227,Lovastatin
,24154936,Cmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],4.22,208406,DB00227,Lovastatin
,24154936,Cmax,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[ng] / [ml],9.30,208407,DB00227,Lovastatin
,24154936,AUC0-t,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],34.65,208408,DB00227,Lovastatin
,24154936,AUC0-t,Simvastatin acid: Tmax were 5.8±1.7 h and 6.5±1.4 h; Cmax were 4.22±2.10 ng/ml and 9.30±8.09 ng/ml; AUC0-t were 34.65±16.89 ng ∙ h/ml and 61.62±46.41 ng ∙ h/ml.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),[h·ng·∙] / [ml],61.62,208409,DB00227,Lovastatin
,24154936,Urine Recovery rate,Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),%,40.55,208410,DB00227,Lovastatin
,24154936,Urine Recovery rate,Urine Recovery rate of total niacin: (40.55±7.38)% and (62.87±12.04)%.,"Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24154936/),%,62.87,208411,DB00227,Lovastatin
,24162379,Peak plasma concentrations,"Peak plasma concentrations ranged from 0.08 to 2.2 and from 0.03 to 0.6 μM for simvastatin lactone and carboxylate, respectively.",Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24162379/),μM,0.08 to 2.2,208771,DB00227,Lovastatin
,24162379,Peak plasma concentrations,"Peak plasma concentrations ranged from 0.08 to 2.2 and from 0.03 to 0.6 μM for simvastatin lactone and carboxylate, respectively.",Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24162379/),μM,0.03 to 0.6,208772,DB00227,Lovastatin
,23180162,relative bioavailability,"In vivo, the relative bioavailability of SIM from super-SEDDDS increased significantly to 180 ± 53.3% (p = 0.014) compared to the dosing of two capsules of (dose equivalent) 75% drug-loaded SNEDDS.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),%,180,209588,DB00227,Lovastatin
,23180162,terminal half-life of elimination,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),h,2.3,209589,DB00227,Lovastatin
,23180162,terminal half-life of elimination,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),h,1.4,209590,DB00227,Lovastatin
,23180162,area under the curve ratio,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),,0.57,209591,DB00227,Lovastatin
,23180162,area under the curve ratio,"A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine.",Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180162/),,0.90,209592,DB00227,Lovastatin
,1904355,oral absorption,"Radiolabelled studies demonstrated oral absorption and bioavailability values of 34% and 17%, respectively.","Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,34,210347,DB00227,Lovastatin
,1904355,bioavailability,"Radiolabelled studies demonstrated oral absorption and bioavailability values of 34% and 17%, respectively.","Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,17,210348,DB00227,Lovastatin
,1904355,plasma elimination half-life,Peak blood level after oral administration is reached at approximately 1 h and the mean plasma elimination half-life is 1.8 h.,"Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),h,1.8,210349,DB00227,Lovastatin
,1904355,Binding,Binding of total radioactivity to plasma proteins averages 45%.,"Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,45,210350,DB00227,Lovastatin
,18724669,flow rate,"Simvastatin and the internal standard (lovastatin) were extracted from human plasma with diethyl ether-n-hexane-isopropanol (80: 20 : 3, v/v/v), then separated on a Waters ACQUITY UPLC BEH C18 column (50 mm x 2.1 mm, 1.7 microm) with isocratic elution at a flow rate of 0.25 mL/min.",[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),[ml] / [min],0.25,211995,DB00227,Lovastatin
,18724669,m/z,2 --> m/z 199.0 and m/z 405.,[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),,199.0,211996,DB00227,Lovastatin
,18724669,m/z,2 --> m/z 199.0 and m/z 405.,[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),,405,211997,DB00227,Lovastatin
,18724669,0 --> m/z,"0 --> m/z 199.0 was used to quantify simvastatin and the internal standard, respectively.",[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),,199.0,211998,DB00227,Lovastatin
,18724669,extraction recovery,The mean extraction recovery of simvastatin was 91.6%.,[Determination of simvastatin in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18724669/),%,91.6,211999,DB00227,Lovastatin
,27200472,flow rate,"The analytes were analyzed on an Acquity UPLC BEH C18 column, and a gradient program was applied at a flow rate of 0.2mL/min.",Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC-MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200472/),[ml] / [min],0.2,212506,DB00227,Lovastatin
,27200472,extraction recoveries,"The average extraction recoveries were 90.1% and 91.9% for LOV and LOVA, and the matrix effects were found to be between 85% and 115%.",Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC-MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200472/),%,90.1,212507,DB00227,Lovastatin
,27200472,extraction recoveries,"The average extraction recoveries were 90.1% and 91.9% for LOV and LOVA, and the matrix effects were found to be between 85% and 115%.",Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC-MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27200472/),%,91.9,212508,DB00227,Lovastatin
,11833826,AUC(0-24) ratio,"The AUC(0-24) ratio for lovastatin was 1.91 (90% CI, 1.77 - 3.35), reflecting higher bioavailability of the prodrug with lovastatin ER; in contrast, the ratios for lovastatin acid and active and total inhibitors of HMG-CoA reductase were < 1.","A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11833826/),,1.91,214111,DB00227,Lovastatin
<,11833826,AUC(0-24) ratio,"The AUC(0-24) ratio for lovastatin was 1.91 (90% CI, 1.77 - 3.35), reflecting higher bioavailability of the prodrug with lovastatin ER; in contrast, the ratios for lovastatin acid and active and total inhibitors of HMG-CoA reductase were < 1.","A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11833826/),,1,214112,DB00227,Lovastatin
,15045696,fractional catabolic rate (FCR),"Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P <.03), and there was a significant correlation between FCR and the peak LDL diameter of the injected fractions (R(2) =.71, P <.034).",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.050,215035,DB00227,Lovastatin
,15045696,fractional catabolic rate (FCR),"Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P <.03), and there was a significant correlation between FCR and the peak LDL diameter of the injected fractions (R(2) =.71, P <.034).",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.134,215036,DB00227,Lovastatin
,15045696,"k(2,1)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.255,215037,DB00227,Lovastatin
,15045696,"k(2,1)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.277,215038,DB00227,Lovastatin
,15045696,"k(1,2)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.105,215039,DB00227,Lovastatin
,15045696,"k(1,2)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.248,215040,DB00227,Lovastatin
,30632800,polydispersity index,"Optimized nanoparticles showed a particle size of 258 ± 2.4 nm, polydispersity index of 0.32 ± 0.052, and zeta potential of -12.5 mV.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),,0.32,216759,DB00227,Lovastatin
,30632800,zeta potential,"Optimized nanoparticles showed a particle size of 258 ± 2.4 nm, polydispersity index of 0.32 ± 0.052, and zeta potential of -12.5 mV.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),mv,-12.5,216760,DB00227,Lovastatin
,30632800,entrapment efficiency,"The entrapment efficiency of GM and SV in the nanoparticles was 38.5 ± 4.5% and 72.2 ± 5.6%, respectively.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),%,38.5,216761,DB00227,Lovastatin
,30632800,entrapment efficiency,"The entrapment efficiency of GM and SV in the nanoparticles was 38.5 ± 4.5% and 72.2 ± 5.6%, respectively.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),%,72.2,216762,DB00227,Lovastatin
,20171425,C(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],1.68,220946,DB00227,Lovastatin
,20171425,C(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],3.62,220947,DB00227,Lovastatin
,20171425,T(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,10.33,220948,DB00227,Lovastatin
,20171425,T(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.04,220949,DB00227,Lovastatin
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.04,220950,DB00227,Lovastatin
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,11.41,220951,DB00227,Lovastatin
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.16,220952,DB00227,Lovastatin
,20171425,C(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],3.40,220953,DB00227,Lovastatin
,20171425,C(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],5.16,220954,DB00227,Lovastatin
,20171425,T(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,8.40,220955,DB00227,Lovastatin
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.57,220956,DB00227,Lovastatin
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,13.09,220957,DB00227,Lovastatin
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.52,220958,DB00227,Lovastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],8.75,222399,DB00227,Lovastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],5.77,222400,DB00227,Lovastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],3.93,222401,DB00227,Lovastatin
,30776567,Clint,"Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Clint of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein.",Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30776567/),[μl] / [mg·min],2.45,222402,DB00227,Lovastatin
,34214011,AUC(0-t),Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [h·l],2018.58,225449,DB00227,Lovastatin
,34214011,AUC(0-t),Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [h·l],653.05,225450,DB00227,Lovastatin
,34214011,Cmax,Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [l],173.69,225451,DB00227,Lovastatin
,34214011,Cmax,Baicalein significantly increased the AUC(0-t) (2018.58 ± 483.11 vs. 653.05 ± 160.10 μg/L × h) and Cmax (173.69 ± 35.49 vs. 85.63 ± 13.28 μg/L) of simvastatin.,Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),[μg] / [l],85.63,225452,DB00227,Lovastatin
,34214011,IC50,"Baicalein showed an inhibitory effect on the activity of CYP3A4 with the IC50 value of 12.03 μM, which is responsible for the metabolism of simvastatin.",Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214011/),μM,12.03,225453,DB00227,Lovastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,80,226815,DB00227,Lovastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,18,226816,DB00227,Lovastatin
>,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,95,226817,DB00227,Lovastatin
,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,60,226818,DB00227,Lovastatin
,23698259,IC₅₀,"In RHM, GTE inhibited MDZ 1'-hydroxylation with IC₅₀ and K(i)(app) values of 12.5 and 18.8 µg/mL, respectively, in a noncompetitive manner.",Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698259/),[μg] / [ml],12.5,230414,DB00227,Lovastatin
,23698259,K(i)(app),"In RHM, GTE inhibited MDZ 1'-hydroxylation with IC₅₀ and K(i)(app) values of 12.5 and 18.8 µg/mL, respectively, in a noncompetitive manner.",Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698259/),[μg] / [ml],18.8,230415,DB00227,Lovastatin
,21915888,flow rate,"Separation of SV, LV, NIA and the IS was achieved on an Alltima C₁₈ column with a mobile phase consisting of 5 mm ammonium acetate (pH 4.5) and acetonitrile (20:80, v/v) pumped at a flow rate of 1 mL/min.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),[ml] / [min],1,233942,DB00227,Lovastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,2.12,233943,DB00227,Lovastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,1.67,233944,DB00227,Lovastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,0.50,233945,DB00227,Lovastatin
,21915888,Nominal retention times,"Nominal retention times obtained for SV, LV, NIA and IS were 2.12, 1.67, 0.50 and 0.65 min, respectively.","Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21915888/),min,0.65,233946,DB00227,Lovastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB00227,Lovastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB00227,Lovastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB00227,Lovastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB00227,Lovastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB00227,Lovastatin
,16028010,irreversible elimination clearances,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238835,DB00227,Lovastatin
,16028010,irreversible elimination clearances,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],18.6,238836,DB00227,Lovastatin
,16028010,CL10,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238837,DB00227,Lovastatin
,16028010,CL20),"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238838,DB00227,Lovastatin
,16028010,CL20),"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],18.6,238839,DB00227,Lovastatin
,16028010,CL12,"The formation clearance of SVA from SV (CL12 = 4.8 ml min(-1) kg(-1)) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min(-1) kg(-1)), and the recycled fraction was relatively minor (0.009).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],4.8,238840,DB00227,Lovastatin
,16028010,CL21,"The formation clearance of SVA from SV (CL12 = 4.8 ml min(-1) kg(-1)) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min(-1) kg(-1)), and the recycled fraction was relatively minor (0.009).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.6,238841,DB00227,Lovastatin
,16028010,CL,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],2.9,238842,DB00227,Lovastatin
,16028010,CL12,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],2.9,238843,DB00227,Lovastatin
,16028010,CL20,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],9,238844,DB00227,Lovastatin
,16028010,CL20,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238845,DB00227,Lovastatin
,16028010,CL21,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],9,238846,DB00227,Lovastatin
,16028010,CL21,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238847,DB00227,Lovastatin
,16028010,recycled fraction,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238848,DB00227,Lovastatin
,16028010,recycled fraction,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),,0.00,238849,DB00227,Lovastatin
,16028010,"volume of distribution at steady state (Vss,real)","In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg(-1)) were much larger than the corresponding values of SVA (0.3 L kg(-1)).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[l] / [kg],2.3,238850,DB00227,Lovastatin
,16028010,"volume of distribution at steady state (Vss,real)","In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg(-1)) were much larger than the corresponding values of SVA (0.3 L kg(-1)).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[l] / [kg],0.3,238851,DB00227,Lovastatin
>,16028010,IC50,"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,200,238852,DB00227,Lovastatin
,16028010,IC5),"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,100,238853,DB00227,Lovastatin
,16028010,IC50,"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,18,238854,DB00227,Lovastatin
,32446169,oral bioavailability,"The cholesterol-lowering agent, simvastatin (SIM), is poorly water-soluble and undergoes extensive first pass metabolism, resulting in a low oral bioavailability of approximately 5%.",Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32446169/),%,5,238967,DB00227,Lovastatin
,21730017,half-life,The typical estimated half-life of SB-649868 was 3-6 h - comparable with currently used hypnotic agents.,"Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730017/),h,3-6,242738,DB00227,Lovastatin
,20012601,relative bioavailability,"Consequently, the relative bioavailability of verapamil was also significantly increased (by 76.5%).",Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012601/),%,76.5,243714,DB00227,Lovastatin
,1914380,area under the plasma concentration-time curve,"The mean area under the plasma concentration-time curve for active inhibitors were 606 +/- 346 and 282 +/- 138 ngEq.hr/ml (p = 0.04) in patients and control subjects, respectively.",Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914380/),[h·ngeq] / [ml],606,244423,DB00227,Lovastatin
,1914380,area under the plasma concentration-time curve,"The mean area under the plasma concentration-time curve for active inhibitors were 606 +/- 346 and 282 +/- 138 ngEq.hr/ml (p = 0.04) in patients and control subjects, respectively.",Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914380/),[h·ngeq] / [ml],282,244424,DB00227,Lovastatin
,25731096,relative bioavailability,"It was found that the relative bioavailability of LOV and LOV β-hydroxy acid (LOVA) for the LOV-loaded MN-SLB formulation was 207.2% and 192.1%, respectively.","Development of novel mesoporous nanomatrix-supported lipid bilayers for oral sustained delivery of the water-insoluble drug, lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25731096/),%,207.2,245666,DB00227,Lovastatin
,25731096,relative bioavailability,"It was found that the relative bioavailability of LOV and LOV β-hydroxy acid (LOVA) for the LOV-loaded MN-SLB formulation was 207.2% and 192.1%, respectively.","Development of novel mesoporous nanomatrix-supported lipid bilayers for oral sustained delivery of the water-insoluble drug, lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25731096/),%,192.1,245667,DB00227,Lovastatin
,33368422,Ka,A two-compartment model with first-order absorption (Ka = 1.83 hr-1 ) and first-order elimination (clearance [CL/F] = 292 L/h; volume of distribution in the central compartment [Vc /F] = 1506 L) well described the PKs of simvastatin in dogs.,Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33368422/),1/[h],1.83,247130,DB00227,Lovastatin
,33368422,clearance [CL/F],A two-compartment model with first-order absorption (Ka = 1.83 hr-1 ) and first-order elimination (clearance [CL/F] = 292 L/h; volume of distribution in the central compartment [Vc /F] = 1506 L) well described the PKs of simvastatin in dogs.,Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33368422/),[l] / [h],292,247131,DB00227,Lovastatin
,33368422,volume of distribution in the central compartment [Vc /F],A two-compartment model with first-order absorption (Ka = 1.83 hr-1 ) and first-order elimination (clearance [CL/F] = 292 L/h; volume of distribution in the central compartment [Vc /F] = 1506 L) well described the PKs of simvastatin in dogs.,Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33368422/),l,1506,247132,DB00227,Lovastatin
,10375806,Cmax,"The blood concentration-time curve was fitted to open 2-compartment model, and the pharmacokinetic parameters of Cic alone and Cic + Sim were: Cmax (646 +/- 94) and (698 +/- 340) micrograms.",Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),μg,646,248572,DB00227,Lovastatin
,10375806,Cmax,"The blood concentration-time curve was fitted to open 2-compartment model, and the pharmacokinetic parameters of Cic alone and Cic + Sim were: Cmax (646 +/- 94) and (698 +/- 340) micrograms.",Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),μg,698,248573,DB00227,Lovastatin
,10375806,Tmax,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,1.12,248574,DB00227,Lovastatin
,10375806,Tmax,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,1.13,248575,DB00227,Lovastatin
,10375806,AUC,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),[h·mg] / [l],2.3,248576,DB00227,Lovastatin
,10375806,AUC,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),[h·mg] / [l],2.6,248577,DB00227,Lovastatin
,10375806,T1/2 beta,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,12,248578,DB00227,Lovastatin
,10375806,T1/2 beta,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,23,248579,DB00227,Lovastatin
,19398603,area,"Furthermore, the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0 to 10 hours showed no significant differences among 3 statins (simvastatin: 0.32 +/- 0.09, atorvastatin: 0.31 +/- 0.09, and pitavastatin: 0.31 +/- 0.12).",Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398603/),,0,249583,DB00227,Lovastatin
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB00227,Lovastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB00227,Lovastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB00227,Lovastatin
,34079222,retention times,"The HPLC retention times of AML-B and SIM were 2.10 and 15.52 min, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),min,2.10,263398,DB00227,Lovastatin
,34079222,retention times,"The HPLC retention times of AML-B and SIM were 2.10 and 15.52 min, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),min,15.52,263399,DB00227,Lovastatin
,34079222,percent recoveries,Linearity for AML-B was 5.0-50 ng/mL and 0.01-2.0 µg/mL for SIM with percent recoveries of 92.85-101.53% and 94.51-117.75% for AML-B and SIM.,Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),%,92.85-101.53,263400,DB00227,Lovastatin
,34079222,percent recoveries,Linearity for AML-B was 5.0-50 ng/mL and 0.01-2.0 µg/mL for SIM with percent recoveries of 92.85-101.53% and 94.51-117.75% for AML-B and SIM.,Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),%,94.51-117.75,263401,DB00227,Lovastatin
,34079222,tmax,"The tmax values for AML-B and SIM were 12 and 6 h, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,12,263402,DB00227,Lovastatin
,34079222,tmax,"The tmax values for AML-B and SIM were 12 and 6 h, respectively.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,6,263403,DB00227,Lovastatin
,34079222,tlag,"AML-B was absorbed without any lag time (tlag) while tlag was 6.33 ± 0.81 h for SIM, thus met the study objective.",Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34079222/),h,6.33,263404,DB00227,Lovastatin
,9431828,trough concentrations,Mean trough concentrations of cyclosporine in whole blood were 349 microg l-1 before and 242 microg l-1 after simvastatin administration (P < 0.0001).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[μg] / [l],349,265958,DB00227,Lovastatin
,9431828,trough concentrations,Mean trough concentrations of cyclosporine in whole blood were 349 microg l-1 before and 242 microg l-1 after simvastatin administration (P < 0.0001).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[μg] / [l],242,265959,DB00227,Lovastatin
,9431828,DR/C(SS trough),The average cyclosporine DR/C(SS trough) was significantly increased from 24.5 l h-1 before to 28.9 l h-1 after simvastatin administration (P < 0.05).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[l] / [h],24.5,265960,DB00227,Lovastatin
,9431828,DR/C(SS trough),The average cyclosporine DR/C(SS trough) was significantly increased from 24.5 l h-1 before to 28.9 l h-1 after simvastatin administration (P < 0.05).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[l] / [h],28.9,265961,DB00227,Lovastatin
,32405982,solubility,"SEM and XRD analysis conform; proliposomes are spherical, amorphous in nature, so that it enhances the solubility of SV between 15.01 ± 0.026 and 57.80 ± 0.015 μg/mL in pH 7.4 phosphate buffer.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],15.01,266919,DB00227,Lovastatin
,32405982,solubility,"SEM and XRD analysis conform; proliposomes are spherical, amorphous in nature, so that it enhances the solubility of SV between 15.01 ± 0.026 and 57.80 ± 0.015 μg/mL in pH 7.4 phosphate buffer.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],57.80,266920,DB00227,Lovastatin
,32405982,Tmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),h,2,266921,DB00227,Lovastatin
,32405982,Tmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),h,4,266922,DB00227,Lovastatin
,32405982,Cmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],10.4,266923,DB00227,Lovastatin
,32405982,Cmax,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [ml],21.18,266924,DB00227,Lovastatin
,32405982,AUC0-∞,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [h·ml],67.124,266925,DB00227,Lovastatin
,32405982,AUC0-∞,"The pharmacokinetics of pure SV and SV proliposomes (SVP) in rats were Tmax 2 ± 0.5 and 4 ± 0.7 h, Cmax 10.4 ± 2.921 and 21.18 ± 12.321 μg/mL, AUC0-∞ 67.124 ± 0.23 and 179.75 ± 1.541 μg/mL h, respectively.","Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32405982/),[μg] / [h·ml],179.75,266926,DB00227,Lovastatin
,14612892,half-life,There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean reduction of 70% for simvastatin (P<0.001): the mean half-life of simvastatin was prolonged from 1.4-2.7 h when given together with imatinib.,"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14612892/),h,1.4-2.7,268235,DB00227,Lovastatin
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.07,268540,DB00227,Lovastatin
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.92,268541,DB00227,Lovastatin
< or =,18855612,F(G),"An area of high intestinal extraction (F(G) < or = 0.25) is identified as problematic, as availability of conclusive data is limited in this area.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.25,268542,DB00227,Lovastatin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB00227,Lovastatin
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB00227,Lovastatin
